Bio-Path Holdings raises $2.0M in registered direct offering with common warrants

BIO-PATH HOLDINGS, INC.

Sold 800,000 shares at $2.50/share for gross proceeds ~$2.0M; net proceeds ~$1.7M after fees and expenses.
Issued common warrants to buy 800,000 shares at $2.85; exercisable after 6 months, term 5.5 years.
ROTH Capital Partners acted as placement agent; cash fee of 7.0% of gross proceeds plus expense reimbursement up to $50,000.
Proceeds intended for working capital and general corporate purposes; closing expected November 9, 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIO-PATH HOLDINGS, INC. entered into Purchase Agreements with several institutional and accredited investors valued at gross proceeds of approximately $2.0 million (effective 2022-11-06).

Action: entry
Agreement: equity purchase
Counterparty: several institutional and accredited investors
Value: gross proceeds of approximately $2.0 million
Effective: 2022-11-06

Exact text from the filing

On November 6, 2022, Bio-Path Holdings, Inc. (the “Company”) and several institutional and accredited investors entered into securities purchase agreements (the “Purchase Agreements”), pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 800,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), for a purchase price per Share of $2.50 and gross proceeds of approximately $2.0 million.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-116216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.